Amgen, Molecular Partners Team On Immuno-Oncology Drugs
socalTECH
DECEMBER 19, 2018
Thousand Oaks-based Amgen and Swiss biotech company Molecular Partners AG said Tuesday that the two are in a collaboration and licensing deal, for the commercialization of a molecule aimed at the immuno-oncology area.
Let's personalize your content